Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Arcus Biosciences Inc (NYSE: RCUS) closed the day trading at $23.33 up 1.04% from the previous closing price of $23.09. In other words, the price has increased by $1.04 from its previous closing price. On the day, 0.95 million shares were traded. RCUS stock price reached its highest trading level at $23.62 during the session, while it also had its lowest trading level at $22.66.
Ratios:
For a better understanding of RCUS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’25 when Tang Carolyn C. sold 7,658 shares for $21.88 per share. The transaction valued at 167,590 led to the insider holds 131,544 shares of the business.
Tang Carolyn C. sold 6,810 shares of RCUS for $150,906 on Dec 17 ’25. The General Counsel now owns 124,734 shares after completing the transaction at $22.16 per share. On Dec 16 ’25, another insider, Markus Richard, who serves as the Chief Medical Officer of the company, sold 5,052 shares for $21.88 each. As a result, the insider received 110,559 and left with 70,141 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 2886586624 and an Enterprise Value of 1820022656. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.03 while its Price-to-Book (P/B) ratio in mrq is 5.73. Its current Enterprise Value per Revenue stands at 7.583 whereas that against EBITDA is -4.986.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.77, which has changed by 0.5507052 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $26.40, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 8.07%, while the 200-Day Moving Average is calculated to be 82.37%.
Shares Statistics:
Over the past 3-months, RCUS traded about 1.83M shares per day on average, while over the past 10 days, RCUS traded about 2529600 shares per day. A total of 107.10M shares are outstanding, with a floating share count of 81.35M. Insiders hold about 34.25% of the company’s shares, while institutions hold 53.17% stake in the company. Shares short for RCUS as of 1765756800 were 7830605 with a Short Ratio of 4.27, compared to 1763078400 on 9888340. Therefore, it implies a Short% of Shares Outstanding of 7830605 and a Short% of Float of 9.0100005.
Earnings Estimates
Arcus Biosciences Inc (RCUS) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.01, with high estimates of -$0.79 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$3.48 and -$3.52 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.87, with 4.0 analysts recommending between -$3.54 and -$4.13.
Revenue Estimates
8 analysts predict $24.81M in revenue for. The current quarter. It ranges from a high estimate of $40M to a low estimate of $16M. As of. The current estimate, Arcus Biosciences Inc’s year-ago sales were $36MFor the next quarter, 8 analysts are estimating revenue of $30.28M. There is a high estimate of $55M for the next quarter, whereas the lowest estimate is $16M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $254M, while the lowest revenue estimate was $229M, resulting in an average revenue estimate of $237.5M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $118.8M in the next fiscal year. The high estimate is $225M and the low estimate is $37M.
